Shockwave Medical (NSDQ:SWAV) this week posted first-quarter results that beat the overall consensus on Wall Street. The Santa Clara, California-based company reported profits of $14.5 million, or 39¢ per share, on sales of $93.6 million for the three months ended March 31, for a bottom-line gain from the year prior on sales growth of 193.5%. Earnings […]
Wall Street Beat
Nuwellis rises on Street-beating Q1
Nuwellis (Nasdaq:NUWE) shares ticked up today on first-quarter results that topped the consensus forecast. The Minneapolis-based fluid overload treatment developer — formerly known as CHF Solutions — posted losses of $4.5 million, or 42¢ per share, on sales of more than $1.9 million for the three months ended March 31, 2022, for a bottom-line from […]
DJO parent Enovis beats The Street in Q1
Enovis (NYSE: ENOV) exceeded Wall Street expectations and reaffirmed its guidance during its first earnings release as a stand-alone orthopedic device company. DJO’s Wilmington, Delaware–based parent brought in $375 million in sales during the quarter ended March 31, 2022, a 21% increase from Q1 2021. Adjusted earnings were $20 million, or 37¢ per share, 2 […]
ICU Medical reports a Street-beating Q1
ICU Medical (Nasdaq:ICUI) reported first-quarter results that came in ahead of the consensus earnings per share forecast. The San Clemente, California-based company yesterday evening posted losses of $38.1 million, or $1.61 per share, on sales of $543.1 million for the three months ended March 31, 2022, for a bottom-line slide into the red on sales growth […]
Vicarious Surgical reports wider-than-expected losses in Q1
Vicarious Surgical (NYSE:RBOT) stock was down in after-hours trading after it reported losses that were wider than Wall Street expectations. The Waltham, Massachusetts–based robotic surgery technology developer this evening reported an adjusted net loss of $18.2 million, or 15¢ per share, for the quarter ended March 31, 2022. The loss was more than triple the […]
Glaukos posts Street-beating Q1 results
Glaukos (NYSE:GKOS) this week posted first-quarter results that beat the overall consensus on Wall Street. The San Clemente, California-based company reported profits of $5.4 million, or 11¢ per share, on sales of $67.7 million for the three months ended March 31, for a sales loss of -0.42% compared with Q1 2021. Adjusted to exclude one-time items, […]
Silk Road Medical grows sales 27% in Q1 results
Silk Road Medical (NSDQ:SILK) this week posted first-quarter results that beat the revenue consensus on Wall Street and missed on earnings. The Sunnyvale, California-based stroke treatment tech company reported losses of $16.7 million, or -48¢ per share, on sales of $28.02 million for the three months ended March 31 for sales growth of 27% compared […]
Axonics raises 2022 sales guidance on Street-beating Q1
Axonics Modulation Technologies (Nasdaq:AXNX) reported first-quarter financial results that topped analysts’ consensus forecast. The Irvine, California–based sacral neuromodulation technology developer posted losses of $22.7 million, or 50¢ per share, on sales of $48.4 million for the three months ended March 31, 2022, for a slight bottom-line loss of just over $150,000 year-over-year on sales growth […]
iRhythm stock soars on Street-beating Q1; C-Suite changes continue
iRhythm Technologies (Nasdaq:IRTC) posted first-quarter results that beat the consensus forecast on Wall Street and increased its outlook for the rest of the year, sending the stock up more than 10% by this morning. The San Francisco-based developer of remote external electrocardiogram monitors reported a net loss of $50.6 million, or -$1.71 per share, on […]
Orthofix beats The Street in Q1, reaffirms 2022 guidance
Orthofix (Nasdaq:OFIX) recorded first-quarter financial results that came in ahead of the consensus forecast on Wall Street. The Lewisville, Texas-based orthopedic implant company posted losses of $4.5 million, or 22¢ per share, on sales of $106.4 million for the three months ended March 31, 2022, for a slight bottom-line gain closer to breakeven on sales […]
Insulet posts Street-beating Q1 as Omnipod 5 rollout is ‘progressing very well’
Insulet (Nasdaq:PODD) shares were down after hours despite first-quarter results that topped the consensus forecast. The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months ended March 31, 2022, for a big bottom-line gain from breakeven this time a year ago […]
